Cayman Avasimibe; Purity- Greater Than Or Equal To 98%; Size- 25

Rasagiline-¹³C₃ is intended for use as an internal standard for the quantification of rasagiline (Item No. ) by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC₅₀ = 4.43 nM for the rat brain enzyme). It is selective for MAO-B over MAO-A (IC₅₀ = 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 µM. Rasagiline inhibits rat brain MAO-B in vivo (ED₅₀ = 0.1 mg/kg). It reduces cerebral edema in a mouse model of traumatic brain injury. Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson’s disease. Formulations containing rasagiline have been used in the treatment of Parkinson’s disease.

WARNING This product is not for human or veterinary use.